U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281014) titled 'Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing' on Dec. 03.
Brief Summary: The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Heart Failure
Intervention:
DRUG: Placebo
This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations
1) IV Vehicle infusion plus oral placebo pill 2) IV Vehicle infusion plus oral 25mg spironolactone 3) IV Aldosterone infusion plus oral placebo pill 4) IV Aldoster...